Research paperSHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line
Introduction
Breast cancer is one of the leading aggressive and lethal malignancies worldwide (Torre et al., 2015). In the past decades, due to the development in diagnosis and systemic therapy, including surgery, radiation and chemotherapy, the prognosis of breast cancer is improving. A great amount of evidence showed that multiple proteins are dysregulated in primary tumors and are associated with the development and progression of breast cancers (Wan et al., 2013, Guo et al., 2011, Zeng et al., 2012, Lu, 2012). To enable the development of novel and effective anticancer therapeutics, understanding the roles and molecular mechanisms of these proteins is of great importance.
Src homolog and collagen homolog (Shc), a kind of cell surface receptors adaptor protein, can activate growth factor receptors to signaling pathways, such as insulin receptor (IR), insulin growth factor receptor (IGFR), epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) (Chen et al., 2008, Ornitz and Itoh, 2015, Koul et al., 2013, Qu et al., 2012). SHCBP1 (SHC SH2-binding protein 1), one of the partner of Shc family, has been recently identified in different contexts. Asano et al. showed that Aurora B-mediated SHCBP1 phosphorylation was critical for proper ingression of the cleavage furrow (Asano et al., 2014). SHCBP1 was also identified as a binding partner of central spindlin by proteomics analysis (Buckley et al., 2014). Due to the ability of growth factor receptors activating, SHCBP1 was shown to be play critical role in cell proliferation regulation. SHCBP1 was dysregulated in several diseases especially cancer. SHCBP1 was up-regulated in both human and mouse leukemia and lymphoma (Eckerle et al., 2009, Piccaluga et al., 2007, Kupershmidt et al., 2010, Truffinet et al., 2007). SHCBP1 was also found to be over-expressed inhuman hepatocellular carcinoma (HCC) samples, and inhibition of SHCBP1 reduced cell proliferation and colony formation in HCC cell lines (Tao et al., 2013). However, the exact role of SHCBP1 in cancer especially in breast cancer remains unknown.
In this study, we attempt to unveil the clinical significance and role of SHCBP1 in breast cancer. We found that SHCBP1 was over-expressed in breast cancer tissues compared with adjacent normal tissues (82 of 128, 64%). Over-expressed SHCBP1 was correlated with advanced clinical stage and poorer survival. Ablation of SHCBP1 inhibited the proliferation in vitro. SHCBP1 knockout decreased Ras levels and AKT activity, up-regulated cyclin-dependent kinase inhibitor p21, and down-regulated the Cyclin B1 and CDK1. Our study showed that SHCBP1 may play a role in cell growth and may be a potential diagnosis biomarker and therapeutic target for breast cancer.
Section snippets
Reagents
The antibodies used were anti-SHCBP1 was from ABCAM Biotechnology. Anti-Cyclin B1, anti-p-AKT, anti-p21, anti-CDK1 and anti-GAPDH were all from Santa Cruz Biotechnology (Santa Cruz, USA). All other chemicals were from Sigma-Aldrich Corporation (San Luis, USA) unless otherwise stated.
Cell lines
Breast cancer cell lines MDA-MB-231 and MCF-7 were purchased from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's Modified Eagle's Medium (Gibco)
SHCBP1 over-expression correlates with progression and poor prognosis in breast cancer
To investigate the clinical significance of SHCBP1, 128 human breast cancer tissue samples were analyzed by IHC. IHC analysis indicated that SHCBP1 was markedly up-regulated in breast cancer samples compared with adjacent normal tissues. Moreover, statistical analysis of the results revealed that SHCBP1 expression was strongly associated with the clinical stage (p < 0.001), T classification (p < 0.001), M classification (p < 0.001) and HER2 expression (p < 0.001) (Table 2). Kaplan–Meier survival curves
Discussion
In this study, we showed that SHCBP1 is over-expressed in breast cell tissues. The up-regulation of SHCBP1 is significantly correlated with the clinical stage, T classification, M classification, HER2 expression and poor survival rate in breast cancer. CRISPR/CAS9 lentivirus-mediated knockout technology was performed to specifically knockout SHCBP1 protein expression and demonstrated that loss of SHCBP1 function significantly inhibited cell proliferation and colony formation, and promoted
Acknowledgments
This work was supported by Putuo District of Shanghai Science and Technology Commission research project (No. 2011PTKW007), the Innovation Team of Shanghai Traditional Chinese Medicine and the Key Medical Discipline Project of Shanghai Putuo Distinct.
References (21)
SHCBP1 is required for midbody organization and cytokinesis completion
Cell Cycle (Georgetown, Tex.)
(2014)Unexpected phenotype of mice lacking Shcbp1, a protein induced during T cell proliferation
PLoS One
(2014)EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation
Mol. Biol. Cell
(2008)Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Nat. Biotechnol.
(2013)Multiplex genome engineering using CRISPR/Cas systems
Science (New York, N.Y.)
(2013)Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma
Leukemia
(2009)Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma
Chin. J. Cancer
(2011)RNA-programmed genome editing in human cells
eLife
(2013)- et al.
Role of p38 MAP kinase signal transduction in solid tumors
Genes Cancer
(2013) Ontology-based meta-analysis of global collections of high-throughput public data
PLoS One
(2010)
Cited by (64)
Biological functions and therapeutic potential of SHCBP1 in human cancer
2023, Biomedicine and PharmacotherapyCRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis
2021, International Journal of Biological MacromoleculesSHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer
2021, GenomicsCitation Excerpt :SHCBP1 is required for midbody organization and cytokinesis completion [10]. Studies have proposed that SHCBP1 promotes the cell cycle transition from G1 to S phase and confirmed that SHCBP1 is closely related to the development of breast cancer [12], lung cancer [13], prostate cancer [14] and other malignant tumours. However, whether SHCBP1 plays a role in pancreatic cancer progression has never been reported.
miR-19a/b and miR-20a Promote Wound Healing by Regulating the Inflammatory Response of Keratinocytes
2021, Journal of Investigative DermatologyCRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
2021, Molecular TherapyCitation Excerpt :As overexpression of the SHCBP1 gene is reported in several diseases, especially cancer, it may be a potential therapeutic target as well as a suitable diagnostic biomarker for cancer.42 It has been demonstrated that the CRISPR-Cas9-mediated knockout of the SHCBP1 gene might inhibit cancer cell proliferation and induce apoptosis in breast cancer cells.42 The Kelch-like (KLHL) gene family encodes a group of proteins that are related to several human diseases, along with cancer.76
- 1
These authors contributed to the study equally.